AbCellera nears pivotal Phase 2 data, backed by AI-driven antibody discovery platform and strong liquidity.

AbCellera, known for its antibody platform behind two authorized COVID-19 therapies, has transformed into a clinical-stage biotech firm. It is close to releasing pivotal Phase 2 data for its first fully owned therapy. The company’s platform uses AI to analyze millions of immune cells, supported by a decade of proprietary lab work, offering a unique approach to antibody discovery. With over $650 million in cash and a market cap around $1.6 billion, investors effectively gain access to the platform, pipeline, and about 100 royalty positions. The stock trades near $5, down over 90% from its 2021 peak, presenting a high-risk, high-reward opportunity for investors.